DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021343/S-027, NDA 021379/S-025, NDA 021488/S-025, and NDA 021731/S-023

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC
Attention: Gary Wieczorek
Director, U.S. Regulatory Affairs, Marketed Products
55 Corporate Drive
Bridgewater, NJ 08807

Dear Mr. Wieczorek:

Please refer to your Supplemental New Drug Application (sNDA) dated December 13, 2012, received December 13, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA	Suppl.	Product Name
021343	S-027	Eligard™ (leuprolide acetate) Injection, 7.5 mg
021379	S-025	Eligard™ (leuprolide acetate) Injection, 22.5 mg
021488	S-025	Eligard™ (leuprolide acetate) Injection, 30 mg
021731	S-023	Eligard™ (leuprolide acetate) Injection, 45 mg

These "Prior Approval" supplemental new drug applications propose adding "convulsions" to the Post-Marketing section under ADVERSE REACTIONS as requested in FDA's Supplement Request letter dated November 16, 2012.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susan Jenney, Regulatory Project Manager, at (301) 796-0062.

Sincerely,

{See appended electronic signature page}

Katherine Fedenko, M.S., C.R.N.P.
Deputy Director for Safety
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center of Drug Evaluation and Research

ENCLOSURES:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GENEVIEVE A SCHECHTER
02/27/2013